Rosacea ABIMN Gel (Azelaic Acid / Brimonidine Tartrate / Ivermectin / Metronidazole / Niacinamide) (30 mL)

Rosacea ABIMN Gel is a clinically developed skincare product aimed at managing the common symptoms of rosacea, including facial redness, inflammation, and skin sensitivity. The gel is lightweight and easily absorbed, making it ideal for daily use on sensitive or reactive skin. It helps calm irritation and supports skin recovery while enhancing hydration and overall skin texture. With regular application, Rosacea ABIMN Gel aids in reducing visible redness and promoting a healthier, more balanced complexion.

Rosacea ABIMN Gel works by addressing both the inflammation and moisture imbalance that contribute to rosacea symptoms. Its active ingredients help to constrict dilated blood vessels, reducing redness and swelling. The formulation also strengthens the skin’s barrier, preventing moisture loss and protecting against environmental stressors. Additionally, it soothes irritated nerve endings, easing sensations like burning or stinging. Over time, the gel improves the skin’s resilience, reduces sensitivity, and supports the natural healing process for long-term skin comfort.

Rosacea ABIMN Gel should not be used by individuals who have known allergies to any of its ingredients. Avoid applying the gel on broken, infected, or severely irritated skin as this may worsen symptoms. It is advisable to perform a patch test before applying it to larger areas, especially if you have highly sensitive skin. If you notice persistent itching, redness, or discomfort, discontinue use and consult a healthcare provider. Avoid contact with eyes, lips, and mucous membranes, and keep the product away from children. Use only as instructed and do not exceed the recommended dosage.

While Rosacea ABIMN Gel is generally well tolerated, some users may experience mild side effects during initial use. These may include temporary redness, dryness, itching, or a slight burning sensation at the application site. Such reactions are usually short-lived and resolve as the skin adjusts to the formula. In rare cases, individuals with very sensitive skin may experience more intense irritation or discomfort. If severe reactions occur, it is important to stop using the product and seek medical advice. Most side effects are mild and can be managed by following the recommended usage guidelines.

Pregnant and breastfeeding women should consult their healthcare provider before using Rosacea ABIMN Gel. Although the product is applied topically and generally considered safe, some ingredients may be absorbed through the skin. Hormonal changes during pregnancy or lactation can increase skin sensitivity, making it essential to seek professional advice before beginning treatment. Under proper medical supervision, the gel can be used safely as part of a skincare routine designed to manage rosacea symptoms while minimizing risks to both mother and child.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Del Rosso, James Q. “Azelaic Acid Topical Formulations: Differentiation of 15% Gel and 15% Foam.” The Journal of Clinical and Aesthetic Dermatology 10.3 (2017): 37–40. Print.
2. Fariba Iraji, Ali Sadeghinia, Zabiholah Shahmoradi, Amir Hossein Siadat, Abolfazl Jooya. Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Department of Dermatology, Al-Zahra Hospital.
3. Cutis [01 Jan 1996, 57(1 Suppl):36-45]. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies.
4. Chouela E, Abeldano A, et el. Arch Dematol 1999;135:651-5.
5. del Giudice P, Chosidow O, Caumes E. Ivermectin in dermatology. J Drugs Dermatol 2003;2:13-21.
6. Richard-Lenoble D, Chandenier J, and Gaxotte P. Ivermectin and filariasis. Fundam Clin Pharmacology 2003;17:199-203.
7. Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrobial Chemotherapy 1994;34:195-203.
8. Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999;36:353-373.
9. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004;10:1088-1094.
10. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002;136:13-24.
11. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017;112:212-238.
12. Flagyl (metronidazole tablets) package insert. New York, NY: Pfizer, Inc.; 2021 Mar.
13. Niaspan (niacin extended-release) tablet package insert. North Chicago, IL: Abbott Laboratories; 2015 Apr.
14. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
15. Taylor AJ, Villines TC, Stanck EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009. Epub ahead of print, doi:10.1056/NEJMoa907569.
16. Lee JMS, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787—94.
17. McKenney JM, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
18. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag 2006;2(4):337-346.
19. Adkins JC, Balfour JA. Brimonidine A review of its pharmacological properties and clinical potential in management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998;12(3):225-241.
20. Two AM, Wu W, Gallo RL, et al. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015 May: 761-770.
21. Finacea (azelaic acid) topical gel package insert. Whippany, NJ: Bayer Healthcare; 2016 Aug.
22. Finacea (azelaic acid) 15% topical foam package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2015 Jul.
23. Alphagan P (brimonidine 0.1% and 0.15% ophthalmic solution) package insert. Irvine, CA: Allergan; 2013 Sept.
24. Mirvaso (brimonidine) topical gel. Fort Worth, TX: Galderma laboratories; 2016 Jul
25. Lumify (brimonidine 0.025% ophthalmic solution) product label. Bridgewater, NJ: Bausch and Lomb, Inc; 2019 Apr.
26. Brimonidine 0.2% ophthalmic solution package insert. Bridgewater, NJ: Bausch and Lomb Incorporated; 2018 Jun.
27. Qoliana (brimonidine 0.15% ophthalmic solution) package insert. Fort Worth, TX: Alcon Laboratories, Inc; 2012 Mar.
28. Johnson SM, Martinez M, Freedman S. Management of glaucoma in pregnancy and lactation. Surv Ophthalmol. 2001;45:449-54.
29. Madadi P, Koren G, Freeman DJ, et al. Timolol concentrations in breast milk of a woman treated for glaucoma: calculation of neonatal exposure. J Glaucoma 2008;17:329-31.
30. US Food and Drug Administration (FDA). FDA Medwatch: ivermectin intended for animals: letter to stakeholders – do not use in humans as a treatment for COVID-19. Retrieved April 14, 2020. Available on the World Wide Web at:https://www.fda.gov/safety/medical-product-safety-information/ivermectin-intended-animals-letter-stakeholders-do-not-use-humans-treatment-covid-19.– LinkOpens in New Tab
31. US Food and Drug Administration (FDA). FDA Medwatch consumer updates: why you should not use ivermectin to treat or prevent COVID-19. Retrieved March 8, 2021. Available on the World Wide Web at: https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19.– LinkOpens in New Tab
32. Stromectol (ivermectin) package insert. Whitehouse Station, NJ: Merck and Co., Inc.; 2018 Feb.
33. Soolantra (ivermectin) package insert. Fort Worth, TX: Galderma Laboratories; 2018 Apr.
34. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.
35. Sklice (ivermectin lotion) package insert. Atlanta, GA: Arbor Pharmaceuticals; 2017 Jun.
36. Sklice OTC (ivermectin lotion) package insert. Atlanta, GA: Arbor Pharmaceuticals; 2020 Oct.
37. Metronidazole injection package insert. Deerfield, IL: Baxter Healthcare Corporation; 2021 Mar.
38. Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.
39. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.
40. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23.
41. Altin C, Kanyilmaz S, Baysal S, et al. QT interval prolongation due to metronidazole administration. Anadolu Kardiyol Derg 2011;11:46-9.
42. Cohen O, Saar N, Swartzon M, et al. First report of metronidazole-induced QT interval prolongation. Int J Antimicrob Agents 2008;31:180-81.
43. Woosley RL, Heise CW, Gallo T, et al. QTFactors List. Oro Valley, AZ: AZCERT, Inc.; Accessed March 31, 2020. Available on the World Wide Web at: https://crediblemeds.org/ndfa-list/– LinkOpens in New Tab
44. Flagyl ER (metronidazole extended release tablets) package insert. New York, NY: Pfizer, Inc.; 2021 Mar.
45. Flagyl (metronidazole capsules) package insert. New York, NY: Pfizer, Inc.; 2021 Mar.
46. Metrogel (metronidazole gel), 1% package insert. Fort Worth, TX: Galderma Laboratories, L.P.; 2011 Oct.
47. Metrogel (metronidazole gel 1%) package insert. Forth Worth, TX: G.D. Galderma Laboratories; 2011 Oct.
48. MetroCream (metronidazole 0.75% topical cream). Forth Worth, TX: Galderma Laboratories, L.P.; 2002 Dec.
49. Metrogel-Vaginal (metronidazole gel) package insert. Bristol, TN: Graceway Pharmaceuticals, LLC; 2007 Apr.
50. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines 2015. MMWR. 2015;64(3):1-137
51. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991-1003.
52. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
53. Vandazole (metronidazole vaginal gel 0.75%) package insert. Maple Grove, MN: Upsher-Smith Laboratories, Inc.; 2021 Feb.
54. Muanda FT, Sheehy O, Berard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: A population based cohort study. Br J Clin Pharmacol 2017; July 19 [Epub ahead of print].
55. Muanda FT, Sheehy O, Berard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ 2017;189:e625-e633.
56. Nuvessa (metronidazole vaginal gel 1.3%) package insert. Florham Park, NJ: Exeltis USA, Inc.; 2018 Aug.
57. Passmore CM, McElnay JC, Rainey EA et al. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol. 1988;26:45-51.
58. Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. Obstet Gynecol 1981;57:48-50.
59. Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mother and infants. J Perinat Med 1983;11:114-20.
60. [No authors listed]. An evaluation of metronidazole in the prophylaxis of anaerobic infections in obstetrical patients. J Antimicrob Chemother 1978;4 Suppl C:55-62.
61. Vancocin HCl capsules (vancomycin hydrochloride) package insert. Baudette, MN: Ani Pharmaceuticals, Inc.; 2021 Jan.
62. Vancomycin 10 g bulk intravenous vials package insert. Lake Forest, IL: Hospira, Inc.; 2021 Mar.
63. Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82.
64. Expert Panel: National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89(suppl 2):525-84.
65. Niacinamide. In: Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk. Briggs GG, Freeman RK, Yaffe SJ, (eds.) 7th ed., Philadelphia PA: Lippincott Williams and Wilkins; 2005:1140-1
66. Azelex (azelaic acid) package insert. Irvine, CA: Allergan, Inc.; 2004 May.
67. Azelex (azelaic acid) package insert. Irvine, CA: Allergan, Inc.; 2004 May.
68. Azelex (azelaic acid cream) 20% [package insert]. Irvine, CA: Allergan; 2013.
69. Homeida MM, Bagi IA, Ghalib HW, et al. Prolongation of prothrombin time with ivermectin. Lancet 1988;1:1346-7.
70. Whitworth JA, Hay CR, McNicholas AM, et al. Coagulation abnormalities and ivermectin. Ann Trop Med Parasitol 1992;86:301-5.
71. Richards FO, McNeely MB, Bryan RT, et al. Ivermectin and prothrombin time. Lancet 1989;1:1139.
72. Pacque MC, Munoz B, White AT, et al. Ivermectin and prothrombin time. Lancet 1989;1:1140.
73. MetroLotion (metronidazole 0.75% topical lotion) package insert. Fort Worth, TX: Galderma Laboratories, L.P.; 2015 Oct.
74. Vitazol (metronidazole 0.75% topical cream) package insert. Rochester, NY: Rochester Pharmaceuticals; 2009 Dec.
75. Noritate (metronidazole 1% topical cream) package insert. Bridgewater, NJ: Dermik Laboratories; 2006 Dec.
76. Metronidazole (Metro IV) injection package insert. Bethlehem, PA: B.Braun Medical Inc.; 2021 Apr.
77. Niacor (Niacin tablets) package insert. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2000 Feb.